Sugi Predict

Sugi Predict / Compounds / SCHEMBL304698

SCHEMBL304698

SCHEMBL304698

CSc1nc2ccc(N)cc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 1.00
▸ SMN1; SMN2 Q16637 5/20 0.61
▸ PKM P14618 3/20 0.60
▸ MAPT P10636 9/20 0.56
▸ MEN1 O00255 5/20 0.56
▸ KMT2A Q03164 5/20 0.56
▸ ALDH1A1 P00352 5/20 0.56
▸ LMNA P02545 1/20 0.56
▸ HPGD P15428 3/20 0.53
▸ SHMT2 P34897 1/20 0.53
▸ RAB9A P51151 4/20 0.53
▸ NPC1 O15118 3/20 0.53
▸ KDM4E B2RXH2 3/20 0.53
▸ GLA P06280 3/20 0.53
▸ GAA P10253 3/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.51
▸ NFKB1 P19838 1/20 0.51
▸ NFKB2 Q00653 1/20 0.51
▸ RELA Q04206 1/20 0.51
▸ CA1 P00915 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2332449 0.86 KEAP1 (0.75) KEAP1SMN1; SMN2PKMMAPTMEN1
SCHEMBL865987 0.85 KEAP1 (0.74) KEAP1SMN1; SMN2PKMMAPTMEN1
SCHEMBL10521779 0.84 KEAP1 (0.72) KEAP1SMN1; SMN2PKMMAPTMEN1
SCHEMBL617400 0.81 KEAP1 (0.69) KEAP1SMN1; SMN2PKMMAPTMEN1
SCHEMBL7867881 0.80 KEAP1 (0.67) KEAP1SMN1; SMN2PKMMAPTMEN1
SCHEMBL30602949 0.80 KEAP1 (0.67) KEAP1SMN1; SMN2PKMMAPTMEN1
SCHEMBL10830083 0.79 KEAP1 (0.65) KEAP1SMN1; SMN2PKMMAPTMEN1
SCHEMBL1095273 0.79 KEAP1 (0.65) KEAP1SMN1; SMN2PKMMAPTMEN1
SCHEMBL14327113 0.79 KEAP1 (0.65) KEAP1SMN1; SMN2PKMMAPTMEN1
SCHEMBL1622148 0.79 KEAP1 (0.65) KEAP1SMN1; SMN2PKMMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3933498-A Fogged, direct positive silver halide emulsions containing a bleach inhibiting compound and a Dmin maintainer compound E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-01-20 — — US claimed
EP-4622974-A1 NEW NUCLEIC ACID BINDING COMPOUNDS AND USES bioMérieux (FR) 2025-10-01 — — EP disclosed
WO-2024110392-A1 NEW NUCLEIC ACID BINDING COMPOUNDS AND USES bioMérieux (FR) 2024-05-30 — — WO disclosed
WO-2024110392-A1 NEW NUCLEIC ACID BINDING COMPOUNDS AND USES bioMérieux (FR) 2024-05-30 — — WO disclosed
CN-116926578-A Method for synthesizing heteroaryl thiophenol 新疆大学 2023-10-24 — — CN disclosed
US-11332779-B2 Nucleic acid melting analysis with saturation dyes BIOFIRE DEFENSE, LLC (US) 2022-05-17 — — US disclosed
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2021-05-18 — — US disclosed
US-10828301-B2 2,4-pyrimidinediamine compounds and their uses Rigel Pharmceuticals, Inc. (US) 2020-11-10 — — US disclosed
US-20200248247-A1 Nucleic Acid Melting Analysis with Saturation Dyes UNIVERSITY OF UTAH 2020-08-06 — — US disclosed
US-10709703-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2020-07-14 — — US disclosed
WO-2004038038-A2 AMPLICON MELTING ANALYSIS WITH SATURATION DYES UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2004-05-06 — — WO disclosed
US-20040029902-A1 Antiinflamamtory agents MIDCAP FINANCIAL TRUST 2004-02-12 — — US disclosed
WO-2003063794-A2 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2003-08-07 — — WO disclosed
EP-1308439-A1 PROLINE DERIVATIVES AND USE THEREOF AS DRUGS WELFIDE CORPORATION (JP) 2003-05-07 — — EP disclosed
US-6093716-A Substituted 2-pyrimidineamines and processes for their preparation CELLTECH THERAPEUTICS, LIMITED (GB) 2000-07-25 — — US disclosed
EP-0929549-A1 SUBSTITUTED 2-PYRIMIDINEAMINES, THEIR PREPARATION AND THEIR USE AS PROTEINE KINASE INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 1999-07-21 — — EP disclosed
WO-1998011095-A1 SUBSTITUTED 2-PYRIMIDINEAMINES, THEIR PREPARATION AND THEIR USE AS PROTEINE KINASE INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 1998-03-19 — — WO disclosed
US-5529998-A ANTIBACTERIAL MEDICAMENTS BAYER AKTIENGESELLSCHAFT (DE) 1996-06-25 — — US disclosed
EP-0697412-A1 Benzoxazolyl- and benzo-thiazolyl-oxazolidinones BAYER AG (DE) 1996-02-21 — — EP disclosed
US-3933498-A Fogged, direct positive silver halide emulsions containing a bleach inhibiting compound and a Dmin maintainer compound E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029902-A1 Antiinflamamtory agents FCER2, FCGR1A, HNMT KEAP1 966/4885SMN1; SMN2 4738/4885PKM 3810/4885
US-10709703-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A KEAP1 2064/4885SMN1; SMN2 4764/4885PKM 3841/4885
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A KEAP1 2064/4885SMN1; SMN2 4764/4885PKM 3841/4885
US-10828301-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A KEAP1 2064/4885SMN1; SMN2 4764/4885PKM 3841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.